EU expands approval of Janssen-Cilag's prostate cancer drug Zytiga

01/15/2013 | PharmaTimes (U.K.)

The European Commission approved the use of Janssen-Cilag's Zytiga, or abiraterone acetate, in combination with prednisolone or prednisone, for patients with metastatic castration-resistant prostate cancer who do not respond to androgen deprivation and for whom chemotherapy is not indicated. The drug's approval in the U.S. was expanded recently to include men with metastatic castration-resistant prostate cancer before chemotherapy.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL